Predicting restenosis of drug-eluting stents placed in real-world clinical practice derivation and validation of a risk model from the EVENT registry

Circulation: Cardiovascular Interventions

Volumn 3, Issue 4, 2010, Pages 327-334

  Stolker, Joshua M ^a   Kennedy, Kevin F ^a   Lindsey, Jason B ^a   Marso, Steven P ^a   Pencina, Michael J ^b   Cutlip, Donald E ^a   Mauri, Laura ^b   Kleiman, Neal S ^c   Cohen, David J ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Drug eluting stents; Percutaneous coronary intervention; Restenosis; Risk assessment

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGISTER; SAPHENOUS VEIN GRAFT; TARGET LESION REVASCULARIZATION;

ADULT; AGE FACTORS; AGED; ANGIOPLASTY; CATHETERIZATION, PERIPHERAL; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK ASSESSMENT; SOFTWARE VALIDATION;

EID: 78650136922     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.946939     Document Type: Article

References (36)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119:3198-3206.
2. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-2009. (Pubitemid 46740352)
3. Jeremias A, Ruisi CP, Kirtane AJ, Lee T, Sylvia B, Pinto DS, Ho KK, Cutlip DE, Carrozza JP Jr, Cohen DJ. Differential outcomes after sirolimus-eluting stent implantation: Comparing on-label versus off-label patients in the 'real world.' Coron Artery Dis. 2008;19:111-115. (Pubitemid 351317375)
4. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000. (Pubitemid 46740351)
5. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358: 342-352. (Pubitemid 351159233)
6. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478-1481.
7. Roy P, Buch AN, Javaid A, Okabe T, Raya V, Pinto Slottow TL, Steinberg DH, Smith K, Xue Z, Gevorkian N, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101: 293-299. (Pubitemid 351162956)
8. Spertus JA, Nerella R, Kettlekamp R, House J, Marso S, Borkon AM, Rumsfeld JS. Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. Circulation. 2005;111:768-773. (Pubitemid 40259719)
9. Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Holmes DR Jr. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: Insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 2004;109:2727-2731. (Pubitemid 38737919)
10. Daemen J, Kukreja N, Van Twisk PH, Onuma Y, de Jaegere PP, Van Domburg R, Serruys PW. Four-year clinical follow-up of the rapamycineluting stent evaluated at Rotterdam Cardiology Hospital registry. Am J Cardiol. 2008;101:1105-1111.
11. Lemos PA, Serruys PW, Van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadDen E, Sianos G, Hofma SH, Smits PC, Van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195. (Pubitemid 38114138)
12. Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, Kleiman N. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J. 2005;150:887-892. (Pubitemid 41607758)
13. SulliVan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23:1631-1660. (Pubitemid 38660414)
14. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, Ro YM, Lim DS. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart. 2006;92:1119-1124. (Pubitemid 44125234)
15. Kornowski R. Drug-eluting stent in saphenous vein graft lesions. Catheter Cardiovasc Interv. 2008;71:894-895. (Pubitemid 351951306)
16. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, Slottow TL, Smith K, Torguson R, Xue Z, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol. 2008;102:530-534.
17. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919-928.
18. Vermeersch P, Agostoni P, Verheye S, Van Den Heuvel P, Convens C, Bruining N, Van Den BranDen F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423-2431. (Pubitemid 44895571)
19. Vermeersch P, Agostoni P, Verheye S, Van Den Heuvel P, Convens C, Van Den BranDen F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-267. (Pubitemid 47039289)
20. Kelbaek H, Thuesen L, Helqvist S, Klovgaard L, Jorgensen E, Aljabbari S, Saunamaki K, Krusell LR, Jensen GV, Botker HE, Lassen JF, Andersen HR, Thayssen P, Galloe A, Van Weert A. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol. 2006;47:449-455. (Pubitemid 43063270)
21. Pinkerton CA, Slack JD, Van Tassel JW, Orr CM. Angioplasty for dilatation of complex coronary artery bifurcation stenoses. Am J Cardiol. 1985;55:1626-1628. (Pubitemid 15059299)
22. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30:1428-1436. (Pubitemid 27486458)
23. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109:476-480. (Pubitemid 38168509)
24. Mercado N, Boersma E, Wijns W, Gersh BJ, Morillo CA, de Valk V, Van Es GA, Grobbee DE, Serruys PW. Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001;38:645-652. (Pubitemid 32835730)
25. Sobel BE. Acceleration of restenosis by diabetes: Pathogenetic implications. Circulation. 2001;103:1185-1187. (Pubitemid 32221336)
26. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323. (Pubitemid 37186209)
27. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. (Pubitemid 38067635)
28. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112: 2175-2183. (Pubitemid 41475813)
29. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-2278. (Pubitemid 38678518)
30. Azzarelli S, Amico F, Galassi AR, Giacoppo M, Argentino V, Fiscella A. Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis. J Invasive Cardiol. 2008;20:62-66. (Pubitemid 351271443)
31. Lasala JM, Cox DA, Morris DL, Breall JA, Mahoney PD, Horwitz PA, Shaw D, Hood KL, Mandinov L, Dawkins KD. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. Am J Cardiol. 2009;103: 1663-1671.
32. Arnold SV, Decker C, Ahmad H, Olabiyi O, Mundluru S, Reid KJ, Soto GE, Gansert S, Spertus JA. Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decisionmaking. Circ Cardiovasc Qual Outcomes. 2008;1:21-28.
33. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, Van Den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
34. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz RE. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089. (Pubitemid 36005891)
35. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842. (Pubitemid 30643610)
36. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients: The PURSUIT Investigators. Circulation. 2000;101:2557-2567. (Pubitemid 30350632)